logo
logo
GH Research PLC

GH Research PLC

NASDAQ•GHRS
CEO: Mr. Florian Schonharting M.Sc. (Econ)
セクター: Healthcare
業種: Biotechnology
上場日: 2021-06-25
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
連絡先情報
Joshua Dawson House, Dawson Street, Dublin, D02 RY95, Ireland
353-1-437-8334
www.ghres.com
時価総額
$911.83M
PER (TTM)
-21.2
34.3
配当利回り
--
52週高値
$19.51
52週安値
$7.98
52週レンジ
58%
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$0.23+0.00%
直近4四半期の推移

フリーCF

-$14.48M+17.64%
直近4四半期の推移

2024 FY 決算ハイライト

主なハイライト

GH001 TRD Trial Success Primary endpoint met in TRD Phase 2b trial; GH001 achieved -15.2 point MADRS reduction versus placebo on Day 8.
Research Spending Rises Research and development expenses increased $5.2 M to $35.0 M in 2024, driven by advancing clinical trial activities.
Cash Reserves Remain Strong Cash and equivalents totaled $100.8 M as of December 31, 2024, supporting operations for at least the next 12 months.
GH002 Phase 1 Complete Completed Phase 1 pharmacology trial for intravenous candidate GH002 in healthy volunteers; top-line results available.

リスク要因

Expect Continued Operating Losses Incurred net loss of $39.0 M in 2024; expects significant operating losses to continue for the foreseeable future.
FDA Hold Response Pending FDA clinical hold on GH001 IND requires toxicology studies; planned response submission scheduled for mid-2025.
Need Substantial Additional Funding Requires substantial additional funding to pursue growth strategy; failure to raise capital delays development programs or commercialization.
Mebufotenin Scheduling Risk Mebufotenin is Schedule I in US; rescheduling required for marketing, dependent on FDA approval and DEA action.

見通し

Resolve GH001 FDA Hold Preparing complete response to FDA clinical hold regarding GH001 device bridging data; planned submission mid-2025.
Complete GH001 Extension Phase Open-label extension phase for TRD trial on track for last patient visit completion in first quarter of 2025.
Advance GH002 Program Anticipate developing intravenous candidate GH002 further following completion of Phase 1 pharmacology trial results.
Establish Commercial Capabilities Plans to establish sales, marketing, distribution, and commercial infrastructure to support potential future product approvals.

同業比較

売上高 (TTM)

Akebia Therapeutics, Inc.AKBA
$225.07M
+32.5%
Valneva SEVALN
$198.55M
+13.5%
Geron CorporationGERN
$183.40M
+522.1%

粗利益率 (最新四半期)

Nanobiotix S.A.NBTX
100.0%
+0.0pp
Arbutus Biopharma CorporationABUS
97.9%
-2.1pp
Kura Oncology, Inc.KURA
84.5%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
TYRA$1.49B-15.0-35.8%2.0%
NBTX$1.23B-19.176.7%113.4%
SVRA$1.14B-10.5-86.6%21.2%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月26日
|
EPS:-$0.29
|
売上高:-
財務レポート
財務データ
全年度

  • Form 20-F/A - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年7月29日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.75-10.3%
    不明

  • Form 20-F - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|修正版データを参照

  • Form 20-F - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.68-385.7%
    不明

  • Form 20-F/A - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年6月2日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.14+22.2%
    不明

  • Form 20-F - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年3月9日|修正版データを参照

  • Form 20-F - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年3月28日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.18-1124.5%
    不明